Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Assets for 18 consecutive years, with $26.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 5.14% year-over-year to $26.1 billion; the trailing twelve-month figure through Jun 2026 stood at $106.3 billion (down 3.86% YoY), and the FY2025 full-year result was $26.8 billion, changed 0.1% from the prior year.
• Non-Current Assets fell to $26.1 billion in Q2 2026 per TEVA's latest filing, from $26.3 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $34.6 billion in Q1 2022 and bottomed at $26.1 billion in Q2 2026.
• Historically, Non-Current Assets has averaged $29.7 billion across 5 years, with a median of $30.1 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets retreated 13.62% in 2024, then climbed 0.1% in 2025.
• Over 5 years, Non-Current Assets stood at $32.0 billion in 2022, then fell by 3.02% to $31.0 billion in 2023, then declined by 13.62% to $26.8 billion in 2024, then gained by 0.1% to $26.8 billion in 2025, then dropped by 2.63% to $26.1 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $26.1 billion, $26.3 billion, and $26.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.